TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo

Oncotarget

Volumn 8, Issue 7, 2017, Pages 11708-11718

  Wu, Jing ^a   Li, Shuang ^a   Yang, Yang ^a   Zhu, Shan ^a   Zhang, Mingyou ^a   Qiao, Yuan ^a   Liu, Yong Jun ^a,b   Chen, Jingtao ^a  

^a JILIN UNIVERSITY   (China)

^b Immunology and Inflammation Development Franchise   (United States)

Author keywords

Breast cancer; CpG; Imiquimod; Plasmacytoid dendritic cells; Toll like receptor

Indexed keywords

GRANZYME B; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; AMINOQUINOLINE DERIVATIVE; GRANZYME; GZMB PROTEIN, MOUSE; IMIQUIMOD; INTERFERON INDUCING AGENT; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE; TNFSF10 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CONTROLLED STUDY; FEMALE; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE MIGRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; DENDRITIC CELL; DISEASE MODEL; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; TRANSPLANTATION;

AMINOQUINOLINES; ANIMALS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GRANZYMES; IMMUNOTHERAPY, ADOPTIVE; INTERFERON INDUCERS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 85012881488     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14315     Document Type: Article

References (36)

1. Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006; 35:459-483.
2. Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res 2011; 17:959-964.
3. Clark EA. Regulation of B lymphocytes by dendritic cells. J Exp Med 1997; 185:801-803.
4. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20:621-667.
5. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23:275-306.
6. Ait-Oufella H, Sage AP, Mallat Z, Tedgui A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res 2014; 114:1640-1660.
7. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-267.
8. Adachi K, Davis MM. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells. Proc Natl Acad Sci U S A 2011; 108:1549-1554.
9. Sawant A, Ponnazhagan S. Role of plasmacytoid dendritic cells in breast cancer bone dissemination. Oncoimmunology 2013; 2:e22983.
10. Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012; 72:5188-5197.
11. Dietel B, Muench R, Kuehn C, Kerek F, Steinkasserer A, Achenbach S, et al. MCS-18, a natural product isolated from Helleborus purpurascens, inhibits maturation of dendritic cells in ApoE-deficient mice and prevents early atherosclerosis progression. Atherosclerosis 2014; 235:263-272.
12. Dubrot J, Duraes FV, Potin L, Capotosti F, Brighouse D, Suter T, et al. Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4(+) T cell tolerance. J Exp Med 2014; 211:1153-1166.
13. Wang R, Zhang JL, Wei B, Tian Y, Li ZH, Wang L, et al. Upregulation of plasmacytoid dendritic cells in glioma. Tumour Biol 2014; 35:9661-9666.
14. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008; 118:1165-1175.
15. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122:575-585.
16. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod-and IFN-alpha-mediated antitumor reactivity. J Immunol 2012; 188:1583-1591.
17. Guery L, Dubrot J, Lippens C, Brighouse D, Malinge P, Irla M, et al. Ag-presenting CpG-activated pDCs prime Th17 cells that induce tumor regression. Cancer Res 2014; 74:6430-6440.
18. Karrich JJ, Jachimowski LC, Uittenbogaart CH, Blom B. The plasmacytoid dendritic cell as the Swiss army knife of the immune system: molecular regulation of its multifaceted functions. J Immunol 2014; 193:5772-5778.
19. Lelaidier M, Diaz-Rodriguez Y, Cordeau M, Cordeiro P, Haddad E, Herblot S, et al. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells. Oncotarget 2015; 6:29440-29455. doi: 10.18632/oncotarget.4984.
20. Di Domizio J, Demaria O, Gilliet M. Plasmacytoid dendritic cells in melanoma: can we revert bad into good? J Invest Dermatol 2014; 134:1797-1800.
21. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-7474.
22. Sisirak V, Faget J, Vey N, Blay JY, Menetrier-Caux C, Caux C, et al. Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013; 2:e22338.
23. Kini Bailur J, Gueckel B, Pawelec G. Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer. J Transl Med 2016; 14:151.
24. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, et al. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget 2016. doi: 10.18632/oncotarget.10290.
25. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013; 73:4629-4640.
26. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165:5133-5142.
27. Holcmann M, Stoitzner P, Drobits B, Luehrs P, Stingl G, Romani N, et al. Skin inflammation is not sufficient to break tolerance induced against a novel antigen. J Immunol 2009; 183:1133-1143.
28. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6:1258-1266.
29. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003; 63:9016-9022.
30. Riboldi E, Daniele R, Cassatella MA, Sozzani S, Bosisio D. Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. Immunobiology 2009; 214:868-876.
31. Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005; 65:5020-5026.
32. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123:2447-2463.
33. Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, Kanzler S, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res 2009; 69:855-862.
34. Colisson R, Barblu L, Gras C, Raynaud F, Hadj-Slimane R, Pique C, et al. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood 2010; 115:2177-2185.
35. Loschko J, Heink S, Hackl D, Dudziak D, Reindl W, Korn T, et al. Antigen targeting to plasmacytoid dendritic cells via Siglec-H inhibits Th cell-dependent autoimmunity. J Immunol 2011; 187:6346-6356.
36. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204:1441-1451.